Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Report Date: June 8, 2023
Reporting Period: First quarter ended March 31, 2023
Context: This filing serves to announce the release of financial results for the first quarter of 2023. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The filing explicitly states that the full text of the press release containing the results is furnished as Exhibit 99.1. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in this specific document. The filing acts as a notification of the results rather than a comparative analysis. Investors must refer to Exhibit 99.1 for comparative data.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on June 8, 2023, but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are listed in this cover sheet. The filing includes a standard disclaimer that the information in the press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated June 8, 2023) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an Emerging Growth Company (indicated as checked in the filing) and its implications for financial reporting standards.
- Confirm the liquidity position and runway, as biotech firms often operate with negative cash flows.
- Check for any subsequent events or updates to the Q1 2023 results released after June 8, 2023.